



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet

of

Application Number

10/035,100
------------

Filing Date

December 28, 2001

First Named Inventor

Erik Ho Fong Wong, et al.

### Art Unit

1614

Examiner Name

Phyllis G. Spivack

Attorney Docket Number

00378.US1 (PC02976)
---------------------

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**EXPRESS MAIL NO. EU807929741US**  
**DOCKET NO. 00378.US1 (PC24976)**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/035,100
Filing Date	December 28, 2001
First Named Inventor	Erik Ho Fong Wong, e
Art Unit	1614
Examiner Name	Phyllis G. Spivack
Attorney Docket Number	00378.US1 (PC02976)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		E. ARAGUES, et al., "Reboxetine in Negative Symptoms of Schizophrenia", European Psychiatry, 2000, pp 426S, ABSTRACT ONLY	
		G. SCHUTZ, et al., "Reboxetine Add on Therapy to Haloperidol in The Treatment of Schizophrenia: a Preliminary Double-blind Randomized Placebo-controlled Study", International Clinical Psychopharmacology, 2001, pp 275-278, Vol. 16, No. 5	
		E. SPINA, et al, "No Effect of Reboxetine on Plasma Concentrations of Clozapine, Risperidone, and Their Active Metabolites", 2001, pp675-678, Vol. 23 No. 6	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.